Both the authors have equally contributed to this work.
Supplementation With a New Therapeutic Oxygen Carrier Reduces Chronic Fibrosis and Organ Dysfunction in Kidney Static Preservation
Article first published online: 22 AUG 2011
© 2011 The Authors Journal compilation © 2011 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 11, Issue 9, pages 1845–1860, September 2011
How to Cite
Thuillier, R., Dutheil, D., Trieu, M. T. N., Mallet, V., Allain, G., Rousselot, M., Denizot, M., Goujon, J.-M., Zal, F. and Hauet, T. (2011), Supplementation With a New Therapeutic Oxygen Carrier Reduces Chronic Fibrosis and Organ Dysfunction in Kidney Static Preservation. American Journal of Transplantation, 11: 1845–1860. doi: 10.1111/j.1600-6143.2011.03614.x
- Issue published online: 29 AUG 2011
- Article first published online: 22 AUG 2011
- Received 06 December 2010, revised 29 April 2011 and accepted for publication 30 April 2011
- Graft preservation;
- ischemia reperfusion injury;
- kidney transplantation;
- oxygen transporters
Static preservation is currently the most widely used organ preservation strategy; however, decreased donor organ quality is impacting outcome negatively. M101 is an O2 carrier with high-oxygen affinity and the capacity to function at low temperatures. We tested the benefits of M101 both in vitro, on cold preserved LLC-PK1, as well as in vivo, in a large white pig kidney autotransplantation model. In vitro, M101 supplementation reduced cold storage-induced cell death. In vivo, early follow-up demonstrated superiority of M101-supplemented solutions, lowering the peak of serum creatinine and increasing the speed of function recovery. On the longer term, supplementation with M101 reduced kidney inflammation levels and maintained structural integrity, particularly with University of Wisconsin (UW). At the end of the 3-month follow-up, M101 supplementation proved beneficial in terms of survival and function, as well as slowing the advance of interstitial fibrosis. We show that addition of M101 to classic organ preservation protocols with UW and Histidine–Tryptophane–Ketoglutarate, the two most widely used solutions worldwide in kidney preservation, provides significant benefits to grafts, both on early function recovery and outcome. Simple supplementation of the solution with M101 is easily translatable to the clinic and shows promises in terms of outcome.
hemoglobin-based oxygen carrier
histidine tryptophane ketoglutarate
interstitial fibrosis and tubular atrophy
ischemia reperfusion injury
University of Wisconsin
Kidney transplantation remains the therapy of choice for end stage renal diseases. Ischemia reperfusion injury (IRI), inherent to transplantation, strongly correlates with delayed graft function (1,2), chronic graft failure and late graft loss (3–5). IRI is a complex process involving oxidative stress, mitochondrial uncoupling (6,7) and the coagulation cascade (8,9). It also activates innate immune response independently of allogenicity (10), with intense immune cells invasion (11,12). Hence, a better management of organ preservation could limit IRI, improving graft quality and outcome substantially.
Currently, hypothermic cold storage (CS) is the main strategy to minimize ischemic injuries (1,13). CS preservation is based on metabolism reduction with temperature; however, even slow metabolism requires O2. Hence, the concept of introducing O2 during CS is growing. Different approaches are developed: persufflation by retrograde venous application of O2, the two-layer method with perfluorocarbons (PFC) or gaseous oxygenation during CS (14–16). However, their effectiveness remains unclear and translation to the clinic could be difficult considering the important changes in protocol and equipment.
Herein, we investigate a new therapeutic molecule, Hemarina-M101 (M101) (Figure 1A), a respiratory pigment from a marine invertebrate, Arenicola marina, developed as an additive to preservation solutions (18–20). M101 is a giant O2 carrier corresponding to an extracellular hexagonal-bilayer hemoglobin (HBL-Hb). HBL-Hbs are naturally extracellular heminic respiratory pigments of high molecular weight (∼3600 kDa), made of complexes globin and nonglobin linker chains (Figure 1B). Such large complexes represent a summit of complexity for oxygen-binding heme proteins with a remarkable hierarchical organization, each globin chain surrounding and protecting its own heme group, a protoporphyrin ring with an iron atom in center reversibly binding one O2 molecule. This confers a high O2 binding capacity: M101 can carry up to 156 molecules of O2 (Figure 1C). M101 possesses other advantages: O2 is released against a gradient in the absence of allosteric effectors, providing the environment with just the right amount of O2; it functions in a large range of temperature (from 4°C to 37°C) (21,22) and it possesses intrinsic superoxide dismutase (SOD)-like activity linked to Cu/Zn metals (18), all invaluable in IRI (23,24). M101 is also fully identified from gene to protein quaternary structure (25,26). Furthermore, M101 is nonimmunogenic (18). These suggest an important potential towards improving organ preservation by CS.
The concept of supplementing classical organ preservation protocols is rapidly gaining interest (9,27–32). Simple addition of a molecule to an established protocol presents high potential for translation to clinic, compared to more cumbersome approaches of changing solutions and/or machines. We tested the benefits of M101 supplementation in vitro in cold stored cultured cells using a range of solutions used in the clinic, then in vivo with the two most widely used static cold preservation solutions (90% of the world's market) (33): University of Wisconsin (UW) and Histidine Tryptophane Ketoglutarate (HTK). We used a pig model of kidney auto-transplantation, as this species presents an elaborate system of interlobular and segmental arteries to supply the numerous kidney lobes, a characteristic shared with humans and higher mammal but absent in rodents or dogs (6), making porcine models very relevant to mimic human conditions (34,35).
Unless specified, all reagents were purchased from Sigma-Aldrich (Lyon, France).
M101 production and utilization in preservation solutions
M101 (HEMO2life, Hemarina SA, Morlaix, Brittany, France) was manufactured using standard procedures for the extraction of biologics conformed to the specifications of the health authorities. The purified protein is frozen at –80°C then thawed to 4°C before experiment and diluted in a preservation solution: UW (ViaSpan, Bristol-Myers-Squibb, Braine-l'Alleud, Belgium), HTK (Custodiol, Essential Pharmaceuticals, Newton, PA, USA), IGL (IGL-1, IGL Group, Lissieu, France), Celsior (Celsior, Genzyme, Saint-Germain-en-Laye, France), Ringer Lactate (RL, Aguettant, France) or Perfadex (Perfadex, Vitrolife, Sweden).
M101 functional analyses
Oxygen binding: M101 was supplemented (1 g/L) to UW. Either N2 gas or LLC-PK1 cells incorporated to the preparation was used to deoxygenate the solution then both preparations were hermetically sealed. The functionality of M101 was followed by spectrophotometry (36) allowing characterization of oxyhemoglobin (HbO2) and deoxyhemoglobin (deoxy-Hb; Figure 2). Absorption spectra were recorded over the 390–650 nm range (UVmc2, SAFAS, Monaco). Dissolved O2 (dO2) was monitored using an O2 sensor (Metler Toledo, France).
SOD activity: M101 SOD activity was evaluated by nitroblue tetrazolium (NBT) assay modified by Oberley and Spitz (39). Briefly, superoxide was generated by xanthine and xanthine oxidase in presence of catalase and DETAPAC. Reduction of NBT was detected by spectrophotometry at 560 nm. KCN was added 1 h at 4°C before starting the experiment to deactivate Cu/Zn-SOD. A Cu/Zn-SOD from bovine erythrocytes was used as a control (Calbiochem).
Decreased absorbance indicates increased scavenging activity. The percentage inhibition of superoxide anion generation was calculated using: [(A0– A1)/A0×100], where A0 is the absorbance of control and A1 is the absorbance of samples.
M101 structural analyses
M101 was supplemented (1 g/L) to solutions, its structure was followed over time by isocratic gel filtration at room temperature with an autosampler set at 4°C employing an HPLC system (Dionex, France) and a 1 cm × 30 cm Superose 6C column (fractional range 5–5000 kDa, GE Healthcare, Vélizy Cedex, France). Flow rate was 0.5 mL/min and the eluate was monitored with a photodiode array detector over the range 250–700 nm. The elution curves were acquired and processed using the Chromeleon software (Dionex, Voisins le Bretonneux, France).
The dissociation curve was obtained normalizing the area of M101 peak at time t (At) with the area of M101 peak at time 0 (At0) and plotted versus time. The GraphPad Prism software (GraphPad Software, La Jolla, CA, USA) was used to fit the curve to linear (f(At/At0) =–kdt, T½= 1/(2kd)) or mono-exponential (f(At/At0) = a × exp[–kdt]) profile. The fit acceptability was judged with the best-correlation coefficient. The dissociation constant (kd) and half-life (T½) were deduced from the best-fitted curve: linear or mono-exponential.
Cell cold-storage experiments
Porcine proximal tubular cell line LLC-PK1 (CL-101, ATCC, LGC Standards, France) were cultured as previously described (40). Cold ischemia injury was simulated by storage of cell monolayer at 4°C under room atmosphere in a preservation solution (UW, HTK, IGL, Celsior, RL or Perfadex) supplemented or not with M101.
Assays were: (1) Necrosis: Lactate dehydrogenase (LDH) release was tested using In Vitro Toxicology Assay Kit; (2) Apoptosis: Caspase-3 activity was determined using Caspase-3 Fluorometric Assay kit (R&D Systems, Lyon, France); (3) Viability: Metabolic activity was determined by MTT assay and (4) Energetic content: Intracellular ATP was determined using Adenosine 5′-triphosphate (ATP) Bioluminescent Assay Kit. Kits were used following the manufacturer's guidelines. Reactions were quantified with a multiplate reader (Victor3, Perkin-Elmer, Waltham, MA).
For each parameter, results were expressed as percentages of measured values in cold-preserved cells versus measured value in cells before injury (control).
In vivo surgical procedures and experimental groups
Large white male pigs (INRA/GEPA, Surgères, France) were prepared as previously described (4) in accordance with French guidelines of the Ethical Committee for Human and Animal Studies. The right kidney was collected, cold flushed and preserved for 24 h before transplantation, a time chosen because it is slightly longer to the cold ischemia time noticed by United Network for Organ Sharing for renal allografts (19.6 ± 8.4 h in 2000) (41). The left kidney was nephrectomized to mimic nephron mass in transplanted situation. Surgical teams were blinded to protocols. Time for vascular anastomoses was 30 ± 5 min, blood loss was minimal and no postoperative complication was observed. Four groups were studied: (1) UW: organ preservation with UW; (2) UW + M101: UW supplemented with 5 g/L M101; (3) HTK: HTK; (4) HTK + M101: HTK supplemented with 5 g/L M101. Controls were sham-operated animals.
Pigs were placed in a metabolic cage for diuresis (mL/24 h), creatinemia (μmol/L), fraction of excreted sodium (%) and proteinuria (g/24 h) measurements as previously described (3–5).
Biopsies were collected 7, 14 days and 1 month after reperfusion. Brush border loss and endoluminal detachment were assessed using a semiquantitative 6-point scale: 0, no abnormality; 1, mild lesions affecting less than 25% of kidney samples; 2, lesions affecting 25–50% of kidney samples; 3, lesions affecting 51–75% of kidney samples; 4, lesions affecting more than 75% of kidney samples and 5, extensive necrosis and renal damage (42).
Quantitative determination of interstitial invasion was adapted from Banff classification (43): 0, no mononuclear inflammatory cell in tubules; 1, Foci with 1 to 4 mononuclear cells per tubular cross-section or ten tubular cells; 2, Foci with 5–10 mononuclear cells per tubular cross-section and 3, Foci with more than 10 mononuclear cells per tubular cross-section.
Tubulointerstitial fibrosis was determined using Picro Sirius staining (44).
Immunohistochemistry was used for ED1+ and CD3+ cell invasion measurement (SouthernBiotech, Birmingham, AL, USA). Quantitative evaluation was performed on 5–10 high-powered fields (200×).
Statistical methods: Means ± SEM or SD are shown. In vitro data were compared using Dunett's test. For in vivo data, the Mann–Whitney U test was used for comparisons between 2 groups (only UW vs. UW + M101 and HTK vs. HTK + M101 comparisons were conducted). Correlations were measured with Spearman's test and dependence of M101 effect on the solution used was tested using a two-way ANOVA. SPSS software (IBM, Armonk, NY, USA) and GraphPad software (GraphP) were used for statistical analyses. Significance was accepted for p < 0.050.
O2 binding: M101 in solution with UW was deoxygenated by N2 flushing or by addition of LLC-PK1 cells. Figure 3 shows data obtained with cells since both set of experiment gave the same results. Under room atmospheric condition, M101 dissolved in UW was oxygenated (HbO2) as shown by absorption spectrum (Figure 3A, normoxia). Then, the preparation was hermetically sealed and O2 consumed by cells (hypoxia). After 75 min of hypoxia, M101 spectrum switched progressively towards deoxy-Hb conformation with a shift of Soret band, a decrease of Beta and Alpha bands and an increase of absorbance around 555 nm (Figure 3B). Complete deoxygenation appeared after 90 min of hypoxia (Figure 3C): spectrum showed Soret with a maximum at 428 nm and a plateau with a maximum at 555 nm, the characteristic spectrum of deoxy-Hb derivative. This state was reversible as oxygenation of the preparation resulted in the initial spectrum of M101 (Figure 3D). The measure of dO2 correlated with the light-absorption spectra (data not shown).
M101 is stable in commercial preservation solutions
The stability of M101 was assayed in UW, HTK, IGL, Celsior, RL and Perfadex. Dissociation constant and half-life show that M101 is stable for long periods of time (Table 1).
M101 protects cells in vitro against cold preservation lesions
Conservation of kidney epithelial cells in the gold standard solution, UW, was very deleterious (Figures 5–8). Assessment of cell viability by LDH release demonstrated a loss of cell viability after 12 h of CS (Figure 5A). No significant activation of caspase-3 was detected (Figure 5B). Metabolic activity (Figure 5C) and ATP content (Figure 5D) were reduced concomitantly to LDH release.
M101 was protective against these events (Figure 6): as little as 0.312 g/L was sufficient to significantly improve structural and metabolic integrity and energetic content after 24 h. Total protection was reached at 1.25 g/L of M101 (LDH release: 6 ± 8%; MTT test: 71 ± 13%; ATP content: 78 ± 23%). Cellular energetic content was upregulated with concentrations higher than 2.5 g/L (ATP content >120% compared to control). M101 also protected renal cells in a time and concentration dependent manners (Figure 7): cellular integrity was totally preserved (LDH release < 20%) for 24 h at 1.25 g/L, 36 h at 2.5 g/L, 48 h at 5 g/L and 72 h at 10 g/L.
Experiments were reproduced with other solutions (Figure 8): RL (Figure 8A), Perfadex (Figure 8B), HTK (Figure 8B), IGL (Figure 8D) and Celsior (Figure 8E). As for UW, conservation in these solutions induced cell structural and/or functional damages (respectively, Figures 8a and b). Two kinds of results were obtained: (1) similarly to UW, cells cold-stored in RL and, in a lesser extent, in Perfadex presented both structural and functional injuries; (2) cells cold-stored in HTK, IGL or Celsior presented only functional injuries. In every solution, M101 supplementation protected both cell integrity and cell functionality (LDH release <20% in all conditions and MTT test: 50–100%).
In vivo kidney graft function recovery is faster with M101
Pigs transplanted with UW + M101-preserved kidney resumed urine production at day 1 (versus day 2 for UW), and had a faster recovery to stabilized urine production levels by day 4 (Figure 9A, p = 0.016). HTK groups had equivalent diuresis recoveries (Figure 9B). Serum creatinine levels in UW group showed high levels peaking at day 3 and slowly decreasing afterwards. UW + M101 animals showed significantly lower levels peaking at day 1 and recovered pretransplant levels by day 7 (p = 0.009 at all time points, Figure 9C). HTK animals showed a high serum creatinine peak at day 1, followed by a slow recovery remaining above pretransplant levels while HTK + M101 animals had a significantly lower peak at day 1 (p = 0.009) and a faster recovery to pretransplant level by day 11 (Figure 9D). Sodium reabsorption measurements showed significantly superior performance in M101 preserved kidneys compared to solution alone, confirming better recovery (Figures 9E and F).
Tissue integrity is better preserved in M101 grafts
Evaluation of brush border loss and cell detachment, typical IRI tubular lesions, revealed important damage in UW grafts at days 7 and 14, stabilizing at month 1 (Figure 10; Table 2, top panel). UW + M101 kidneys showed less extended lesions. HTK groups showed a similar trend towards amelioration of histological lesions by M101.
Inflammation is less severe in M101 kidneys
There was an important immune response development in UW grafts throughout the duration of the follow-up (Table 2, middle–bottom panel). Kidneys preserved in UW + M101 showed little immune infiltration early on, and reduced signs of inflammation later. HTK groups both showed low-level infiltration. At 3 months, invasion of both innate (ED1+) and adaptative (CD3+) immune cells revealed decreased levels of invasion in M101 preserved kidneys compared to the solution alone.
|Groups||Brush Border Loss||Endoluminal detachment|
|UW||3.5 ± 1.1||2.6 ± 0.9||2.1 ± 0.3||3.1 ± 0.3||2.5 ± 0.6||2.0 ± 0.1|
|UW + M101||2.0 ± 1.4||2.0 ± 1.5||1.8 ± 0.4||0||0||0|
|HTK||3.5 ± 0.6||2.3 ±1.2||1.8 ± 0.4||1.0 ± 0.1||0||0|
|HTK + M101||3.0 ± 1.6||1.5 ± 0.6||1.4 ± 0.5||1.0 ± 0.5||0||0|
|UW||3.1 ± 0.4||3.2 ± 0.3||2.6 ± 0.4||3.2 ± 0.4||3.1 ± 0.2||3.0 ± 0.3|
|UW+M101||0.0 ± 0.01||1.0 ± 0.6||1.0 ± 0.0||0||0||1.0 ± 0.1|
|HTK||1.5 ± 0.6||1.3 ± 1.2||1.2 ± 0.4||0.8 ± 0.9||0.7 ± 0.6||1.2 ± 0.4|
|HTK+M101||1.5 ± 0.9||1.2 ± 0.5||1.2 ± 0.4||1.0 ± 0.5||0.5 ± 0.6||1.0 ± 0.1|
|CD3+ at 3 month||ED1+ at 3 month|
|UW||17.0 ± 2.0||12.5 ± 1.5|
|UW+M101||6.9 ± 0.41||9.5 ± 0.4|
|HTK||23.0 ± 1.4||17.3 ± 3.2|
|HTK+M101||14.2 ± 3.92||6.6 ± 1.22|
Outcome is improved by M101 supplementation
Pigs were euthanized at 3 months, time at which we previously demonstrated development of chronic fibrosis in this model (Figure 11) (45,46). Development of interstitial fibrosis and tubular atrophy (IFTA) in UW grafts was extensive (23%), while M101 supplementation significantly reduced it (11%, p = 0.049; Figure 11E). HTK kidneys also demonstrated important IFTA development (25%). Here also, addition of M101 significantly reduced damage development (10%, p = 0.038).
M101 supplementation correlates with better early and 3-month outcomes
Further statistical analysis showed that M101 supplementation was negatively correlated with creatinine levels at day 3 (R2= 0.75, p = 0.0001) and sodium excretion levels at day 3 (R2= 0.74, p = 0.0001). Moreover, we determined that M101 supplementation was also negatively correlated with chronic outcome (3 months): creatinine (R2= 0.75, p = 0.0001), proteinuria (R2= 0.55, p = 0.013) and fibrosis (R2= 0.78, p = 0.0001). Two-way ANOVA revealed that there was an interaction between M101 and the solution used for acute outcome: creatinemia (p = 0.001) and sodium reabsorption (p = 0.04) at day 3; while chronic M101 effects at 3 months were independent of the solution used (data not shown).
Herein, we describe the benefits of M101 supplementation on cold stored cells in vitro and on kidney grafts stored with either UW or HTK. M101 supplementation increased cell resistance to IRI and correlated with improved early function recovery and better long-term outcome with less chronic fibrosis and amelioration of function.
M101 is a new therapeutic molecule, an extracellular respiratory pigment from marine organism, developed as an additive to preservation solutions. This O2 carrier has peculiar assets for organ preservation such as high oxygen affinity, ability to function at low temperatures and anti-oxidative activity. We demonstrated the oxygenation ability of M101 in CS conditions. O2 binding and release occurs passively in a simple O2 gradient and in absence of allosteric effector. M101 is characterized by a P50, corresponding to 50% of the O2 saturation. When the PO2 is below the P50, oxygen is released passively from M101 and consumed by cells or tissues. This is a dynamic equilibrium process dependant on cellular needs, when a O2 site becomes free, it will be reused by a new O2 molecule. We also confirmed that this molecule possesses a Cu/Zn-SOD activity, which is of high value in the context of IRI (18,23,24).
In vitro, progressive CS causes a significant and progressive (1) increase in cell LDH release, (2) reduction in metabolic activity and (3) reduction in energetic content. Twenty-four hours of CS resulted in almost complete loss of structural viability, functional viability and energetic content. The majority of cell death was likely due to necrosis, as shown by LDH test, rather than apoptosis since caspase-3 activity did not change. M101 protected renal cells in a time- and dose-dependent manner, independently of the solution used. LDH release in HTK, IGL and Celsior was at low levels without M101 so the addition of M101 had no additional effect on this parameter. The benefit of M101 is more evident by MTT assay, which is in accordance to a study showing superiority of MTT assay sensitivity over LDH release assay on the evaluation of metabolic activity (47).
M101 supplementation increased cellular ATP content, reflecting superior maintenance of energetic metabolism, likely decreasing the need to switch from mitochondrial respiration to anaerobic glycolysis and protecting the mitochondria. Maintenance of high ATP levels during preservation by M101 may also benefit the restoration of energy homeostasis upon reperfusion due to less metabolic stress on oxidative pathways.
In vitro results lead us to adopt 5 g/L in vivo, allowing for possible discrepancies between in vitro 2D culture and in vivo 3D tissue. In the later setting, we characterized the effects of M101 supplementation in a porcine autologous transplantation model particularly well adapted for studying IRI, the target of M101. An allograft setting may have biased the findings, for instance with side effects from immunosuppression.
We preserved kidneys with either HTK or UW, the most widely used solutions in the world (Eurotransplant and UNOS data ), for 24 h. As current preservation time average 18 h, with a trend towards increasing, our choice of 24 h appears justified. Furthermore, 24 h provides the amount of IR damage adapted for a proof of concept. While we did not evaluate in vivo benefits on shorter preservation times, demonstration of M101 benefits on shorter preservation time are likely, considering the impact of the molecule in vivo after 24 h preservation and the protection demonstrated on in vitro studies for shorter preservation times.
The differences between UW and HTK have been the object of several publications and since this study was not designed to compare these solutions, we will focus our discussion on the impact of M101 on their performance separately. Use of M101 was correlated with improved early recovery of function, particularly in grafts preserved with UW. Since the intensity of IRI is directly correlated to the occurrence of delayed graft function in patients (1,2), it is expected that M101 will be efficient in reducing IRI in vivo in preserved kidney graft.
Histologically, IRI is characterized by extensive tubular damage, such as loss of brush border, and intense immune cell infiltration (11,12). Indeed, IRI was shown to be capable to induce inflammatory processes in an antigen-independent fashion (10). M101 supplementation was effective in protecting against these damages early on, likely through direct cell protection as observed in vitro. As stressed cells produce danger signals inducing inflammation and cell invasion (48), reduction of these mechanisms by M101 supplementation was likely due to better cell protection.
IFTA is the pivotal marker of chronic loss of graft function, and ultimately loss of the grafts itself (49). We therefore measured the development of IFTA in parallel with function loss at 3 months and determined that classical preservation solutions could not avoid extensive fibrosis development as well as loss of function. However, supplementation with M101 at the time of preservation correlated with diminished development of fibrosis, preserving function and improving outcome. In our in vivo model, free of any effects due to immunosuppression (50), we observed the summated effects of damage sustained by organ preservation and reperfusion (51) and our data outlines the importance of an optimized preservation protocol.
Providing O2 to ischemic tissue during CS could however be a “double-edged sword,” as O2 can also fuel oxidative stress if the cell is not capable of restoring oxidative respiration (52). Herein, we showed that the use of an O2 carrier during static preservation was protective, allowing cold-preserved cells to maintain their stock of ATP, hence presenting a balanced energy metabolism at reperfusion and being able to handle the sudden influx of O2 without excessive oxidative stress activation.
Alternative carriers are possible, such as PFCs (14,16), which through the use of the two-layers method (53) showed interesting potential in pancreas (54) and small bowels (55) preservation. However, PFCs have the inconvenient of being hydrophobic, lipophilic and difficult to sterilize (56). Moreover, O2 binding by PFCs needs high O2 partial pressures, which implies a continuous O2 supply during the preservation period and which raises the problem of hyperoxia and oxidative stress (57), possibly complicating their use in the clinic. Furthermore, recent data on pigs showed that the two layer method was not advantageous for kidney preservation (58). Another method consisting of active gaseous oxygenation by retrograde persufflation is also possible and has been shown in a small study to improve initial organ function (59); however, it might be difficult to set up in the clinic. These techniques provides O2 in excess which could induce oxidative stress while a carrier such as M101 has the unique property of providing O2 against a gradient, according to the physiological need of the cell and in a reversible process as we showed with functionality studies. Hemoglobin-based oxygen carriers are polymerized hemoglobin solutions from human or bovine origin first developed as blood substitute (60,61). However, they have not been used in organ preservation and their use appears difficult, as the function of warm-blooded hemoglobin is uncertain at reduced temperatures. Nonprotein O2 carriers are also included in Lifor (Lifeblood Medical, Freehold, NJ, USA), a new preservation solution, and showed promises in improving resistance to IRI in a rat model of warm ischemia (62). However, protection during hypothermia remains to be demonstrated and thus does not justify a complete change of preservation solution policy in the clinic, while the simple addition of an additive such as M101 has a higher translatability potential.
Moreover, M101 is naturally suited for hypothermic delivery of O2. Indeed, it is derived from a marine organism, produced in a safe and secure environment, subjected to important changes in temperatures and environmental conditions. Evolution has therefore honed it into a most efficient way to transport O2 in an extracellular manner, at low temperatures and with the ability to withstand a harsh environment such as hypoxia. In effect, M101 has been designed by evolution to maintain life in hypoxic and hypothermic conditions for long periods of time, hence is perfectly suited for organ preservation. M101 is thus stable in a wide range of organ preservation solutions of various ionic compositions and osmolarities, and provides both O2 carrying and SOD abilities (18). This technology harnesses the product of millions of years of evolution to target the heart of IRI: lack of O2.
There is currently a rise of interest in regards to machine preservation of grafts (63,64) as it provides important improvement of graft quality and outcome (65). Although its mechanism remains unclear, the washout of metabolites and cellular waste produced during ischemia is a likely hypothesis. The presence of these products at reperfusion is indeed likely associated with the intense activation of the innate immune pathway, in accordance with the danger signal pathway (66,67). In this setting, the addition of M101, to be cycled through the organ to deliver oxygen to its most remote territories, could be a valuable addition and provide additive or synergistic protection for the organ. This important issue is to be investigated in a future study.
In conclusion, we demonstrated herein the beneficial use of a novel O2 carrier in two of the most used preservation solutions. We have demonstrated that the use of M101 in CS protocol is correlated with better short-term function recovery and reduced development of IFTA, main cause of graft loss. It is hoped that, in future, this technique will improve organ preservation not only for conventional organs but also for extended criteria and deceased after cardiac death organs, particularly as organ shortage leads centers towards increasingly marginal donors.
The authors would like to thank Prs Gérard Mauco and Michel Eugene (Inserm U927) and Séverine Deretz (INRA, Surgères) for their help and comments and William Hébrard and Catherine Henry (INRA, Surgères) and Véronique Mahy (Hemarina) for their expert technical assistance. Authors would also like to thank Pr Taveau (UMR CNRS 5248, Université de Bordeaux, France) for his courteous gift of the molecule 3D reconstruction.
Funding Sources: Conseil Général de la Vienne, Région Poitou Charentes, the Banque Tarneaud, Poitiers, CHU de Poitiers and Inserm, the Société Francophone de Transplantation, the French Foundation of Transplantation and the Fondation Centaure (Réseau de recherche en Transplantation). This work has obtained the label of the competitiveness cluster “Pôle Mer Bretagne” (France) and was in part financed by funds of the “Agence National de la Recherche” (France) with the programs Emergence (ANR-05-EMPB-025–01/02) and Research Innovation in Biotechnology (ANR-07-RIB-007–02).
The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest. Co-authors from Inserm, CNRS and UPMC do not have shares in the capital of the company. Co-authors from Hemarina were employed by the company at the time of these studies; furthermore, Franck Zal and Morgane Rousselot are the founders and the main shareholders of HEMARINA. Other authors from HEMARINA are only employed by the company.
- 20Quaternary structure of the extracellular haemoglobin of the lugworm Arenicola marina: A multi-angle-laser-light-scattering and electrospray-ionisation-mass-spectrometry analysis. Eur J Biochem 1997; 243: 85–92., , , , .
- 33Companiesandmarkets.com. Organ preservation solutions – A global strategic business report. 2010. Available at: http://www.companiesandmarkets.com/Summary-Market-Report/organ-preservation-solutions-a-global-strategic-business-report-317184.asp. Accessed June 1, 2010.
- 36Spectrophotometry of haemoglobin derivatives. Assen , The Netherlands : Charles C Thomas Publisher, Royal Vangorcum, 1970., ed.
- 67Toll-like receptors in hepatic ischemia/reperfusion and transplantation. Gastroenter Res Prac 2010; 2010., , .